Editas Medicine, Inc. (EDIT) News
Filter EDIT News Items
EDIT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EDIT News Highlights
- EDIT's 30 day story count now stands at 16.
- Over the past 28 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about EDIT are GENE, DEC and BEAM.
Latest EDIT News From Around the Web
Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
Editas Just Caught a Break Thanks to Vertex PharmaceuticalsEditas isn't out of the woods yet, but it's better off than before. |
Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 23%Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making... |
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeuticsbluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog. |
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent Newsbluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news. |
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy. |
Editas cashes in on CRISPR patent with Vertex dealThe deal, struck after Editas was awarded ownership of a key patent for the landmark gene editing technology, could be the first of many like it. |
S&P 500 Gains and Losses Today: Regional Banks Get a Boost From the FedThe S&P 500 gained 1.4% on Wednesday, Dec. 13, 2023, after the Federal Reserve indicated that it anticipates interest rate cuts next year. |
Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing DealVertex Pharmaceuticals shares hit a record high after the results of a pain medicine study and announcing a gene-editing technology agreement. |
Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance MissU.S. equities were slightly higher at midday Wednesday, Dec. 13, 2023 ahead of a decision on interest rates from the Federal Reserve. |
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the agreement, Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene editin |